COMy 2023 | Rationale behind the development of the novel dynamic PANGEA model
Irene Ghobrial
• 11 May 2023
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, briefly explains the rationale behind the development of the PANGEA model, which aims to better predict an individual’s risk of progression from a precursor condition to multiple myeloma. Dr Ghobrial describes how the PANGEA model uses dynamic biomarkers to calculate a personalized risk score and how it differs from the International Myeloma Working Group (IMWG) 2/20/20 model. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
